Approach of dyslipidemia; as a cardiovascular risk factor

Year 2012, , 89 - 93, 01.05.2012

Serkan Öztürk Selçuk Öztürk

https://doi.org/10.5505/abantmedj.2012.88598

Abstract

Cardiovascular diseases are the leading cause of mortality continues to be all over the world. Dyslipidemia is an important cardiovascular risk factor and preventable with lifestyle changes and drug therapy. Both primary prevention and secondary prevention with lipid-lowering therapy along with lifestyle changes and drug therapy has been shown to decrease the development of cardiovascular events. The risk scoring of patients is one of the important points in the treatment of dyslipidemia. Individuals must be separated according to risk scores for cardiovascular disease and dyslipidemia approach should be planned accordingly this risk scoring.

Keywords

Dyslipidemia, cardiovascular disease, risk factors

Kardiyovasküler risk faktörü olarak dislipidemilere yaklaşım

Abstract

Kalp ve damar hastalıkları tüm dünyada önde gelen mortalite nedeni olmaya devam etmektedir. Dislipidemi ise kalp ve damar hastalıklarında gerek yaşam tarzı değişiklikleri gerek ise ilaç tedavisi ile düzeltilebilen önemli bir risk faktörüdür. Gerek primer koruma amaçlı gerekse sekonder koruma amaçlı lipid düşürücü tedavi ile yaşam tarzı değişiklikleri ve ilaç tedavisi birlikte kardiyovasküler olay gelişiminde azalma olduğu gösterilmiştir. Dislipidemi tedavisinde önemli noktalardan birisi de hastaların risk skorlamasıdır. Bireyler kalp damar hastalıkları açısından risk gruplarına ayrılmalı ve dislipidemi yaklaşımı buna göre planlanmalıdır.

Keywords

Dislipidemi, kalp ve damar hastalığı, risk faktörleri

References

• World Health Organization. Cardiovascular diseases (CVDs) [ online ]. Available from URL: http:// www.who.int/mediacentre/ factsheets/fs317/en/inex.html 2. Murray CJL, Lopez AD Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study Lancet 1997; 349: 1498-1504.
• Emberson JR, Whincup PH, Morris RW Walker M. Re- assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. European Heart Journal 2003; 24: 1719–26.
• World Health Organization. Reducing risks, promoting healthy life. The world health report 2002.
• World Health Organization: Gaining Health: The European Strategy for the Prevention and Control of non- communicable diseases. WHO Regional Committee for Europe www.euro.whu.int/Document/RC56/edoc08.
• De Backer G; EUROASPIRE II Study Group. Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: findings in EUROAS- PIRE II. Atheroscler Suppl. 2002; 13-6;16-7.
• De Sutter J, De Bacquer D, Kotseva K, Sans S, Pyorala K, Wood D, De Backer G; EUROASPIRE II Study Group. Scree- ning of family members of patients with premature coro- nary heart disease; results from the EUROASPIRE II family survey. Eur Heart J. 2003; 24: 249-57.
• Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravas- tatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 Apr 8;350(15):1495-504.
• Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D. Lipid-modifying therapy and attainment of choleste- rol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin. 2005; 21: 1389-99.
• Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Nati- onal Heart, Lung, and Blood Institute;American College of Cardiology
• tion.Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-39.
• De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thom- sen T, Wood D; Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003; 24 :1601- 10.
• Pineda J, Marín F, Marco P, Roldán V, Valencia J, Ruiz- Nodar JM, Romero DH, Sogorb F, Lip GY. The prognostic value of biomarkers after a premature myocardial infarc- tion. Int J Cardiol. 2010; 143: 249-54.
• Streja L, Packard CJ, Shepherd J, Cobbe S, Ford I; WOS- COPS Group. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOS- COPS). Am J Cardiol. 2002; 90: 731-6.
• Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D.Effect of lowering LDL cholesterol substanitially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) Study. Diabetes Care. 2006; 29: 1220-1226.
• Ford I, Blauw GJ, Murphy MB, Shepherd J, Cobbe SM, Bollen EL, Buckley BM, Jukema JW, Hyland M, Gaw A, La- gaay AM, Perry IJ, Macfarlane P, Norrie J, Meinders AE, Sweeney BJ, Packard CJ, Westendorp RG, Twomey C, Stott DJ; The PROSPER Study Group. A Prospective Study of Pra- vastatin in the Elderly at Risk (PROSPER): Screening Expe- rience and Baseline Characteristics. Curr Control Trials Cardiovasc Med. 2002: 20; 8. American Heart
• Associa- 17. Williams B, Lacy PS, Cruickshank JK, Collier D, Hughes AD, Stanton A, Thom S, Thurston H; CAFE and ASCOT Inves- tigators. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study. Circulation. 2009; 119:53-61.
• Spaulding C, Weber S. Scandinavian simvastatin study (4S). Lancet. 1994; 344:8939-8940.
• Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moyé LA, Piller LB, Rutherford J, Simpson LM, Braunwald E. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation. 1999; 19: 216-23.
• MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J, White H. Effects of lowering average of below- average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation. 1998; 97: 1784-90.
• Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, Shui A
• McCabe CH, Braunwald E; PROVE IT-TIMI 22 Investigators. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PRO- VE IT-TIMI 22 study. J Am Coll Cardiol. 2006; 47: 2326-31.
• Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 ran- domised trials of statins. Lancet. 2005; 8: 366(9493):1267- 78.
• Hockley T, Pollard S, Smedley M. Lifestyle and risk factor management and the use of drug therapies in coronary patients from 15 countries. Principal results from EUROAS- PIRE II. European Heart Journal 2001; 22: 554-572.